Literature DB >> 29079598

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Sylvia Herter1, Frank Herting2, Gunter Muth2, Erwin van Puijenbroek1, Tilman Schlothauer2, Claudia Ferrara1, Kevin Brady3, Sabine Lang1, Marina Bacac1, Ekkehard Mössner1, Pablo Umana1, Christian Klein4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29079598      PMCID： PMC5792291          DOI： 10.3324/haematol.2017.178996

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Authors:  Ciara L Freeman; Franck Morschhauser; Laurie Sehn; Mark Dixon; Richard Houghton; Thierry Lamy; Günter Fingerle-Rowson; Elisabeth Wassner-Fritsch; John G Gribben; Michael Hallek; Gilles Salles; Guillaume Cartron
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

2.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

3.  Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies.

Authors:  Thomas R W Tipton; Ali Roghanian; Robert J Oldham; Matthew J Carter; Kerry L Cox; C Ian Mockridge; Ruth R French; Lekh N Dahal; Patrick J Duriez; Philip G Hargreaves; Mark S Cragg; Stephen A Beers
Journal:  Blood       Date:  2015-01-28       Impact factor: 22.113

Review 4.  Obinutuzumab in hematologic malignancies: lessons learned to date.

Authors:  Tim Illidge; Christian Klein; Laurie H Sehn; Andrew Davies; Gilles Salles; Guillaume Cartron
Journal:  Cancer Treat Rev       Date:  2015-07-14       Impact factor: 12.111

5.  Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Authors:  Tilman Schlothauer; Sylvia Herter; Claudia Ferrara Koller; Sandra Grau-Richards; Virginie Steinhart; Christian Spick; Manfred Kubbies; Christian Klein; Pablo Umaña; Ekkehard Mössner
Journal:  Protein Eng Des Sel       Date:  2016-08-29       Impact factor: 1.650

6.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Authors:  Laurie H Sehn; Neil Chua; Jiri Mayer; Gregg Dueck; Marek Trněný; Kamal Bouabdallah; Nathan Fowler; Vincent Delwail; Oliver Press; Gilles Salles; John Gribben; Anne Lennard; Pieternella J Lugtenburg; Natalie Dimier; Elisabeth Wassner-Fritsch; Günter Fingerle-Rowson; Bruce D Cheson
Journal:  Lancet Oncol       Date:  2016-06-23       Impact factor: 41.316

Review 7.  Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies.

Authors:  Marcin Okroj; Anders Österborg; Anna M Blom
Journal:  Cancer Treat Rev       Date:  2012-12-05       Impact factor: 12.111

8.  Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Authors:  Sylvia Herter; Frank Herting; Olaf Mundigl; Inja Waldhauer; Tina Weinzierl; Tanja Fauti; Gunter Muth; Doris Ziegler-Landesberger; Erwin Van Puijenbroek; Sabine Lang; Minh Ngoc Duong; Lina Reslan; Christian A Gerdes; Thomas Friess; Ute Baer; Helmut Burtscher; Michael Weidner; Charles Dumontet; Pablo Umana; Gerhard Niederfellner; Marina Bacac; Christian Klein
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

9.  Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Authors:  Robert Marcus; Andrew Davies; Kiyoshi Ando; Wolfram Klapper; Stephen Opat; Carolyn Owen; Elizabeth Phillips; Randeep Sangha; Rudolf Schlag; John F Seymour; William Townsend; Marek Trněný; Michael Wenger; Günter Fingerle-Rowson; Kaspar Rufibach; Tom Moore; Michael Herold; Wolfgang Hiddemann
Journal:  N Engl J Med       Date:  2017-10-05       Impact factor: 91.245

10.  Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.

Authors:  L Ysebaert; E Laprévotte; C Klein; A Quillet-Mary
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037
View more
  8 in total

1.  FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Authors:  Nada S Alakhras; Jiabin Qiu; Guilherme V Rocha; Derrick R Witcher; Anja Koester; Jinsam You; David A Schaer; Rikke B Holmgaard; Kyla Driscoll; Jeffrey A Willy; Laurent P Malherbe
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

Review 2.  Assessment of Functional Characterization and Comparability of Biotherapeutics: a Review.

Authors:  Rozaleen Dash; Sumit Kumar Singh; Narendra Chirmule; Anurag S Rathore
Journal:  AAPS J       Date:  2021-12-20       Impact factor: 4.009

3.  The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model.

Authors:  Anthony D Marinov; Haowei Wang; Sheldon I Bastacky; Erwin van Puijenbroek; Thomas Schindler; Dario Speziale; Mario Perro; Christian Klein; Kevin M Nickerson; Mark J Shlomchik
Journal:  Arthritis Rheumatol       Date:  2021-03-24       Impact factor: 10.995

4.  High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.

Authors:  Felicitas Rataj; Severin J Jacobi; Stefan Stoiber; Florian Asang; Justyna Ogonek; Nicholas Tokarew; Bruno L Cadilha; Erwin van Puijenbroek; Constanze Heise; Peter Duewell; Stefan Endres; Christian Klein; Sebastian Kobold
Journal:  Br J Cancer       Date:  2018-11-15       Impact factor: 7.640

5.  Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis.

Authors:  Jay Roodselaar; Yifan Zhou; David Leppert; Anja E Hauser; Eduard Urich; Daniel C Anthony
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-03-02

Review 6.  Emerging new therapeutic antibody derivatives for cancer treatment.

Authors:  Shijie Jin; Yanping Sun; Xiao Liang; Xinyu Gu; Jiangtao Ning; Yingchun Xu; Shuqing Chen; Liqiang Pan
Journal:  Signal Transduct Target Ther       Date:  2022-02-07

Review 7.  Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies.

Authors:  Josée Golay; Alain E Andrea; Irene Cattaneo
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

8.  Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.

Authors:  Sophia Stock; Mohamed-Reda Benmebarek; Anna-Kristina Kluever; Diana Darowski; Christian Jost; Kay-Gunnar Stubenrauch; Joerg Benz; Anne Freimoser-Grundschober; Ekkehard Moessner; Pablo Umana; Marion Subklewe; Stefan Endres; Christian Klein; Sebastian Kobold
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.